Expression of Tim-3 on Neutrophils in Ankylosing Spondylitis

Expression of T Cell Immunoglobulin and Mucin-domain Containing Molecule 3 (Tim-3) on Neutrophils as an Indicator to Assess Disease Activity in Ankylosing Spondylitis Patients

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07383805

Enrollment

Registered

2026-02-03

Start date

2026-06-01

Completion date

2029-09-01

Last updated

2026-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankylosing Spondylitis, AS, Tim3

Brief summary

1. To investigate the expression of Tim-3 on neutrophils in ankylosing spondylitis patients and its correlation with disease activity and inflammatory markers. 2. Association of Tim-3 with sacroiliac MRI findings and the hip inflammatory MRI scoring system (HIMRISS) .

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Adult patients (\>18 years) diagnosed as AS according to 2009 ASAS -Classification criteria (8)

Exclusion criteria

-Age below 18 years old. Patients with other autoimmune diseases. infection (cause increase in inflammatory makers) Any patient with ferromagnetic implants or cardiac pacemaker pregnancy Uncontrolled Hypertension renal failure Chronic liver disease Malignancy Diabetes Mellitus

Design outcomes

Primary

Measure	Time frame	Description
To investigate the expression of Tim-3 on neutrophils in ankylosing spondylitis patients	through study completion, an average of 1 year	investigate the expression of Tim-3 on neutrophils in ankylosing spondylitis patients and its correlation with disease activity and inflammatory markers

Countries

Egypt

Contacts

CONTACTEman Safwat, MD

safwateman605@gmail.com01014116158

Outcome results